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Abstract 
Pulmonary vasoconstriction initiates pulmonary vascular remodelling, which, 
when prolonged, leads to the development of pulmonary hypertension.  The 
hypoxia-inducible transcription factors (HIFs), HIF-1α and HIF-2α, are known 
to contribute to the process of hypoxic pulmonary vascular remodelling. Here 
we show that HIF-2α, expressed in pulmonary endothelial cells, is essential 
for hypoxia-induced pulmonary arterial hypertension (PAH). Loss of 
endothelial HIF-2α expression prevented cardiac hypertrophy and vascular 
remodelling.  A key target of HIF-2α in the endothelial cell is the arginase-1 
enzyme, which directly influences vascular remodelling, and indirectly 
regulates nitric oxide synthesis. Deletion of arginase-1 in the pulmonary 
endothelium attenuated many of the pathophysiological symptoms associated 
with PAH, indicating that HIF-2α/arginase expression in endothelial cells is an 
essential feature of pulmonary hypertension. (word count 117) 
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Significance Statement 
We show that the expression of the HIF-2α transcription factor in the 
endothelial cells of the lung is essential for the development of the pulmonary 
hypertension that results from prolonged exposure to low oxygen.  We 
subsequently show that the HIF-2α transcription factors’ control of the 
arginase-1 enzyme is required for the development of pulmonary 
hypertension, and of its resultant vascular remodelling.  This shows that low 
oxygen levels cause a persistent expression, first, of HIF-2α, and then of 
arginase-1, which in turn regulates vascular constriction and the downstream 
changes in extracellular matrix formation; these are the fundamental 
characteristics of the pulmonary arterial hypertension syndrome. 
 
Introduction 
Hypoxia affects vascular flow in mammals in many different ways, but 
significant drops in oxygenation have a particular effect on the lung.  In the 
pulmonary vascular bed, alveolar hypoxia leads to an immediate 
vasoconstrictor response (hypoxic pulmonary vasoconstriction, or HPV) (1).  
This effect is intended to preserve oxygen in the systemic circulation by 
reducing perfusion of regions of the lung with lowered levels of air flow (2). 
The physiological response to localized pulmonary hypoxia can cause 
problems when alveolar hypoxia involves the entire lung. In conditions 
including chronic obstructive pulmonary disease (3), idiopathic pulmonary 
fibrosis (4), and at high altitude (5), HPV leads to persistent increases in 
pulmonary arterial pressures.  This in turn causes reduced plasticity of the 
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vascular bed, sustained pulmonary vascular remodelling and, ultimately, 
debilitating right ventricular hypertrophy and failure(2). 
 
The hypoxia inducible factors (HIFs) are transcription factors and key 
regulators of the molecular response to hypoxia. The targets of HIFs include 
genes controlling vascularization, cellular proliferation, migration, and 
metabolism(6-11).  There have been a number of recent discoveries in human 
genetics that have correlated HIF function with HPV. For example, individuals 
with Chuvash polycythemia, a condition with augmented HIF stability under 
normal oxygen conditions, exhibit enhanced HPV(12). Other mutations 
resulting in increased expression of the HIF genes have been shown to 
augment HPV response (13). 
 
A well-characterized animal model of hypoxia-induced pulmonary 
hypertension involves exposure to chronic hypoxia (CH), typically 10-12% 
inspired oxygen. This results in extensive vascular remodelling, marked 
pulmonary hypertension and right ventricular hypertrophy over a period of a 
few weeks. Exposure to CH in rodents results in vasoconstriction and a 
pattern of vascular remodelling that is reminiscent of humans with hypoxia-
associated pulmonary hypertension (14, 15). 
 
Mice that are hemizygous for either of the HIF isoforms, HIF-1α (16) or HIF-
2α (17), have been shown to have attenuated pulmonary vascular remodelling 
following experimental CH. Conditional deletion of HIF-1α in smooth muscle 
also ameliorates the degree of remodelling in CH(18).  Conversely, mice 
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homozygous for the R200W mutation that causes Chuvash polycythemia, 
which acts in part to stabilize HIF-2α, spontaneously develop pulmonary 
hypertension(19). 
 
HIF-2α is known to modulate the expression of the metalloenzyme arginases 
(Arg1 and Arg2)(20, 21); both of these arginase isoforms play an important 
role in the regulation of L-arginine homeostasis and the production of L-
ornithine for subsequent polyamine and proline synthesis.  These latter are 
key substrates required for endothelial and smooth muscle cell proliferation 
and collagen synthesis (22).  These isoforms are expressed in vascular 
endothelial cells and are known to be critical regulators of L-arginine 
availability and nitric oxide (NO) production via nitric oxide synthases (NOS) 
(23).  NO plays a significant role in the pathogenesis of pulmonary arterial 
hypertension (PAH), with previous studies identifying lower plasma and 
exhaled NO in PAH patients than those found in healthy controls (24). Oral 
supplementation of L-arginine has been suggested to improve hemodynamics 
and exercise capacity in patients with PAH (25).  We have previously 
demonstrated the roles HIF-1α and HIF-2α play in modulating the expression 
of NOS2 and Arg-1/-2 in different vascular beds (20, 26), and how this in turn 
can allow the differential action of the HIF transcription factors to regulate NO 
homeostasis (21).  Under physiological conditions there is sufficient L-arginine 
available in endothelial cells to convert to NO and L-citrulline.  However, 
prolonged exposure to hypoxia increases the expression of the Arg-1/-2 
enzymes, resulting in decreased availability of L-arginine and thus, impaired 
NO production (27).  Conversely, inhibition of arginase activity redirects L-
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arginine back towards NOS, allows increased generation of NO, which can in 
turn alleviate pulmonary hypertension(28). 
 
The mechanisms by which HIF acts in pulmonary vascular remodelling are 
not fully defined; in particular, the role played by the endothelium in this 
process is not well understood.  Here, we delete the HIF isoforms and one of 
their targets, the Arg1 gene, specifically in the pulmonary endothelium (29), 
and show that expression of the HIFα transcription factors in pulmonary 
endothelial cells is an essential aspect of the hypoxic response of the lung, 
with broad influence over the development of pulmonary hypertension. 
 
Results 
Deletion of HIFα isoforms in pulmonary endothelium  
Genetically manipulated mouse strains with conditional alleles of either the 
HIF-1α or -2α isoforms (30, 31) were crossed to mouse strains expressing the 
cre recombinase enzyme under the control of the Alk1- or L1 promoter (L1cre) 
(29).  To determine the pulmonary endothelial specificity of this transgene, we 
analysed the cre activity of adult L1cre mice by crossing with a 
ROSA26Sortm9(CAG-tdTomato) reporter strain. Red fluorescent protein (tdTomato) 
is expressed following Cre-mediated recombination in this strain background 
(Supplementary Figure 1A).  As shown in supplemental data, lung vasculature 
in frozen sections was easily identifiable and strongly fluorescent.  Minimal 
expression of tdTomato was detectable in the endothelium of other tissues 
including heart, spleen and kidney (Supplemental Figure 1B). This is 
consistent with the published specificity of this transgene (29).  Deletion 
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efficiency was assessed in purified lung endothelial cells by quantitative PCR 
(qPCR) and deletion frequency was greater than 80% (Supplemental Figure 
1C), with little or no detectable deletion in other tissues examined. 
 
HIF-2α deletion in the pulmonary endothelium prevents hypoxia-induced 
pulmonary hypertension 
As an initial test of the importance of endothelial HIF-α stabilisation to the 
progression of hypoxia induced-pulmonary hypertension, we exposed wild 
type (WT) and pulmonary endothelial HIF-α deleted mice to normoxic or 
hypoxic (10% O2) normobaric atmospheres for 21 days.  The development of 
pulmonary hypertension was then assessed through the measurement of right 
ventricular systolic pressures (RVSPs), via catheterisation through the jugular 
vein. Right ventricular systolic pressures in L1cre-HIF-2α mice (18.9±1.0 
mmHg, n=11) under normoxic conditions were significantly lower than 
littermate controls (22.4±1.1 mmHg, n=9, p=0.03) mice. However RVSP from 
normoxic L1cre-HIF-1α mice (24.7±1.7 mmHg, n=6) did not differ from WT 
controls (Figure 1A).  The rise in RVSP normally observed following chronic 
hypoxic challenge was essentially absent in mice with pulmonary endothelial 
HIF-2α deletion.  The RVSPs of L1cre-HIF-2α mice following hypoxic 
exposure (26.1±1.6 mmHg, n=7) were not significantly different from those of 
untreated WT mice (22.48±1.19, n=9) and were much lower than the elevated 
values seen in WT littermate controls (41.9±1.8 mmHg, n=12, p<0.0001) and 
L1cre-HIF-1α mice (36.25±2.37mmHg, n=7, p<0.005). 
The ratio of right ventricular weights to those of the left ventricle plus septum 
(RV/LS+S), an indicator of right ventricular hypertrophy, was likewise 
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significantly higher in wild-type (0.316±0.01, n=8, p<0.0001) and L1cre-HIF-
1α (0.323±0.02, n=8, p<0.001) mice exposed to hypoxia, when compared to 
the ratios found in L1cre-HIF-2α (0.209±0.008, n=8) mice (Figure 1B). Both 
red cell counts and hemoglobin values increased while white cell counts 
decreased following exposure to chronic hypoxia (Supplemental Figure 2A 
and B).  Body weights of all sub-groups, although somewhat variable, trended 
towards a decrease following exposure to hypoxia (supplemental figure 2C). 
 
Pulmonary endothelial HIF-2α is essential for vascular remodelling 
Having established that pulmonary endothelial cell-specific deletion of HIF-2α 
protects mice from increasing pulmonary pressures in response to chronic 
hypoxia, we next sought to determine how loss of pulmonary endothelial HIF-
2α affects hypoxia-induced vascular remodelling.  Serial lung sections were 
immunostained for smooth muscle actin (α-SMA), in order to detect changes 
in smooth muscle coverage of the vasculature, and von Willebrand’s Factor 
(vWF) to mark the endothelial cells themselves.  The lungs from both wild-
type and L1cre-HIF-1α mice demonstrated the typical tissue remodelling seen 
following chronic hypoxic challenge (Figure 2A).  As expected, there was an 
increase in α-SMA associated with pulmonary arteries that are in close 
proximity to terminal and respiratory bronchioles (Figure 2A). 
However, little to no remodelling was observed in lung sections from L1cre-
HIF-2α mice (Figure 2A), reflecting the normal RVSPs observed in these 
animals following exposure to chronic hypoxia.  Lung sections were stained 
with Verhoeff’s stain to detect elastin (32) and thus characterize perivascular 
collagen deposition; this was increased in both WT controls and L1cre-HIF-1α 
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mice. However, only minimal staining was seen in the L1cre-HIF-2α mice 
(Figure 2A).  Medial thickening of vessels was then calculated, taking the 
difference in area circumscribed by the external and internal elastic laminae of 
pulmonary vessels associated with bronchioles.  Both WT littermates 
(17.82±0.99%, n=15) and L1cre-HIF-1α (14.55±0.99%, n=7) mice showed 
significantly increased medial thickness following hypoxic conditioning (Figure 
2B).  In comparison, the L1cre-HIF-2α (10.72±0.74%, n=7) mice showed little 
change in medial thickness relative to normoxic animals (8.45%±0.69%, n=7) 
(Supplemental Figure 3). 
Another indication of vascular remodelling is the relative amount of collagen 
deposition in the vasculature.  This was significantly higher in hypoxically 
conditioned WT control and L1cre-HIF-1α mice relative to L1cre-HIF-2α mice 
(Supplemental Figure 4). 
Pulmonary hypertension is also characterised by structural changes to the 
distal pulmonary vascular bed, including the presence of increased smooth 
muscle in small peripheral pulmonary arteries.  Pulmonary endothelial 
deletion of HIF-2α reduced smooth muscle cell coverage after hypoxic 
exposure, with very little α-SMA staining evident in the small peripheral 
vessels in these animals (Figure 3).  In comparison, both WT littermate control 
and L1cre-HIF-1α mice developed full and partial rings of α-SMA positive 
cells around vessels in hypoxia-conditioned animals (Figure 3). 
 
Reduced Arginase expression in HIF2α mutant mice 
Previous work from our laboratory and others has demonstrated that the two 
HIFα isoforms act to control NO homeostasis during hypoxia.  This occurs at 
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least in part through HIF1α regulation of the NOS2/iNOS gene, and HIF-2α 
regulation of the Arg-1 and Arg-2 genes (20, 21, 26, 33, 34). The enzyme Arg-
2 in particular has been implicated in reducing airway NO and promoting 
remodelling and collagen deposition in PAH patients (35, 36).   We found that 
the hypoxia up-regulation of both arg-1 and -2 was completely lost in hypoxia-
conditioned isolated pulmonary endothelial cells (Supplemental Figure 5A) 
and whole lung samples from L1cre-HIF-2α mice relative to WT littermate 
controls (Figure 4A).   
Consistent with these data, we found that plasma NO(X) concentrations were 
significantly reduced in HIF-1α mice and elevated in the HIF-2α mutant mice 
compared to WT control mice (Figure 4B); these observations fit a model 
whereby reduced arginase expression leads to increased availability of L-
arginine, and increased NO from NO synthase.  
Several recent studies have highlighted the role of endothelin-1(ET-1) in 
pulmonary hypertension, with elevated expression of this vasoactive agent in 
a number of patients. The promoter of ET-1 contains HIF transcription factor 
binding sites, hypoxia response elements (HRE); these sites bind both HIF-1α 
and HIF-2α (37, 38).  However, initial investigations in purified lung 
endothelial cells from wild-type and L1cre-HIF-2α mice showed little change in 
ET-1 expression after 24 hours exposure to hypoxia (Supplemental Figure 
5B).  Furthermore, the gene expression of ET-1 in the lungs of L1cre-HIF-1α 
and L1cre-HIF-2α mice was did not differ from levels seen in wild type 
controls following chronic hypoxic challenge (21 days at 10% O2) 
(Supplemental Figure 5C).  There was a trend towards a decrease in plasma 
ET-1 in both L1cre-HIF1α and L1cre-HIF2α mice following acute hypoxia, and 
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a statistically significant decrease in plasma ET-1 in L1cre-HIF2α mice 
following chronic hypoxia, when compared to wild type controls (Supplemental 
Figure 5D) 
 
Pulmonary endothelial arginase-1 deletion attenuates PAH 
Having established that pulmonary endothelial expression of Arg-1 is 
significantly reduced in the L1creHIF-2α mouse following chronic hypoxic 
exposure, we next sought to determine how the specific deletion of arginase-1 
in the pulmonary endothelium influenced the development of PAH.  The 
increase in RVSP normally observed following chronic hypoxic challenge (wt, 
41.7±0.8mm/Hg, n=7, p<0.0001) was significantly attenuated in mice with 
pulmonary endothelial arginase-1 deletion (31.2±1.0mmHg, n=7) (Figure 5A). 
Of note, the basal RVSP in L1cre-arg1 mice under normoxia (23.0±0.7mmHg, 
n=6) were similar to those seen in littermate WT control mice (24.3±0.3mmHg, 
n=5).  The ratio of right ventricular weight to left ventricle plus septum 
(RV/LS+S) was significantly higher in wild-type (0.39±0.01, n=6, p<0.001) 
when compared to L1cre-arg1 (0.33±0.01, n=9) mice, following chronic 
hypoxic exposure (Figure 5B). Both red cell counts and hemoglobin scores 
increased to a similar degree following hypoxic exposure (Supplemental 
Figure 6A). Wild type littermates showed significantly greater medial 
thickening (18.57%, n=15) when compared to L1cre-arg1 mice (14.35%, n=9) 
after exposure to chronic hypoxia (Figure 5C).  Similarly, the L1cre-arg1 mice 
showed substantially less α-SMA associated with pulmonary arteries in close 
proximity to terminal bronchioles when compared to wild type controls 
(Supplemental Figure 6B). Staining for α-SMA was also substantially reduced 
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in the peripheral pulmonary vasculature of these mutants (Figure 5D).  Given 
the importance of Arginase as a regulator of L-arginine availability and NOS-
mediated NO production, plasma NO(x) levels were analysed, as described 
above.  Deletion of pulmonary endothelial arg-1 significantly elevated plasma 
NO(x) relative to the levels seen in plasma from wild type control mice (Figure 
5E) 
 
 
Discussion 
The distribution of blood flow through all vascular beds is regulated through 
constant adjustments to vascular tone.  In the lung, these changes 
preferentially restrict blood flow to areas low in oxygen (2), in contrast to most 
systemic capillary networks, which react to hypoxia by increasing 
vasodilation(39, 40).  This response by the pulmonary vasculature is complex, 
involving virtually all cell types of the lung, and can drastically alter lung 
vascular morphology over time.  Remodelling of the pulmonary vasculature is 
the primary issue in pulmonary hypertension, leading as it does to decreased 
cardiac and pulmonary function.  In this study, we have shown that the 
endothelial cell specifically is a necessary element in these changes, and that 
the HIF isoform HIF-2α is in turn required for that endothelial response in 
hypoxia-induced PH.  We also observed the down-regulated expression of 
arginase in isolated pulmonary endothelial cells and whole lungs from L1cre-
HIF2a mice following chronic hypoxia, and demonstrate here that deletion of 
arginase-1 specifically in the pulmonary endothelium attenuated the 
development of hypoxic pulmonary hypertension.  Given the role of HIF-2α in 
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regulating arginases specifically, this indicates that a key aspect of the 
function of HIF-2α in PAH is its regulation of arginase expression. 
 
The pulmonary vascular response to acute hypoxia was first described by von 
Euler and Liljestrand approximately 75 years ago, and although the 
physiological consequences are well understood, the molecular regulation of 
the response, including its cellular components, is less clear (41).  The HIF 
pathway has been implicated in this process for some time, initially through 
demonstrations showing that mice hemizygous for HIF-1α or HIF-2α have 
diminished levels of pulmonary hypertension (17, 42).  These studies 
demonstrated the importance of the HIF pathway in the etiology of PAH, and 
subsequent work was able to show that hemizygosity for HIF-1α resulted in 
changes in myocyte hypertrophy and polarization (16).  In contrast, 
hemizygosity of HIF-2α revealed that endothelial changes resulting in PAH 
were partially blocked when HIF-2α was diminished.(17) 
 
More recent work has revealed that tissue-specific loss of HIF-1α in vascular 
smooth muscle results in some attenuation of hypoxia-induced pulmonary 
hypertension, but had no effect on a number of other pathologies associated 
with this syndrome; for example, this deletion had no effect on cardiac 
remodelling.(18) 
 
These data indicate that both HIF isoforms might play a role in the 
pathogenesis of hypoxia-induced PAH, however the individual roles of the two 
major isoforms of HIF, HIF-1α and HIF-2α, and the principal cell types 
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involved was still uncertain. To address these questions we utilized a cre-
recombinase transgene whose expression is restricted to the cells of the 
pulmonary endothelium (29). As described above, we found that in the 
pulmonary endothelium, HIF-2α, but not HIF-1α, plays a fundamental role in 
the development of PAH.  Loss of HIF-2α essentially eliminated both 
pulmonary vascular remodelling and the cardiovascular effects of chronic 
hypoxic exposure. 
Chronic environmental hypoxia results in pulmonary vascular remodelling, 
which elevates pulmonary vascular resistance, and leads to right ventricular 
pressure overload (43).  Structural changes include the appearance of smooth 
muscle-like cells in small pulmonary arterioles and medial and adventitial 
thickening of muscular and elastic vessels (44). In this study, hypoxia failed to 
induce smooth muscle accumulation in the pre-capillary vessels in HIF-2α 
pulmonary endothelial mutant animals, and the medial thickening of vessels 
associated with terminal bronchi was also substantially reduced.  These data 
are quite similar qualitatively to the effects seen in hemizygous HIF-2α mice, 
pointing to the pulmonary endothelium as the dominant cell type in mediating 
the effect of HIF-2α during pulmonary hypertensive remodelling. 
 
Collagen accumulation contributes to pulmonary artery stiffening in hypoxic 
induced pulmonary hypertension.  In clinical studies an increase in pulmonary 
artery stiffness has been found to be a strong predictor of mortality in patients 
with PAH (45).  In this report, prolonged exposure of wild-type and L1cre-HIF-
1α mice to hypoxia resulted in a significant accumulation of collagen around 
bronchial associated arteries; in comparison, deletion of pulmonary 
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endothelial HIF-2α significantly reduced collagen accumulation, likely 
contributing to the lower RVSP seen in these animals. 
 
Hypoxic modulation of endothelin-1 has been suggested by several studies as 
a potential mechanism driving hypoxic pulmonary vasoconstriction (17, 46, 
47). Although we cannot discount a role for pulmonary endothelial derived ET-
1 in the development of PAH, we observed similar acute hypoxic changes in 
plasma ET-1 expression following deletion of either of the HIF-α isoforms.  
Further investigations are clearly required to clarify the link between 
endothelin-1, HIFα expression, and PAH. 
 
The causal link between pulmonary hypertension and NO homeostasis has 
been extensively documented (35, 48), and this is reflected clinically in the 
finding that intrapulmonary nitrates, biochemical reaction products of NO in 
bronchoalveolar fluid, and exhaled NO are all diminished in human pulmonary 
hypertension (24, 49).  Interestingly, primary pulmonary endothelial cells 
isolated from PAH patients have substantially increased expression of arg-2 
(36), which would be predicted to decrease available L-arginine and reduce 
NOS-derived NO formation.  We have previously shown that both Arg1 and 
Arg2 are HIF-2α-dependent genes, and we show here that their expression in 
pulmonary endothelium is decreased in HIF-2α pulmonary endothelium 
mutants.  This should result in an increase in pulmonary endothelial NO, 
which itself has been shown to alleviate PAH experimentally (50).  Consistent 
with this hypothesis, genetic deletion of arg-1 resulted in a marked attenuation 
in the pathologies associated with PAH. Given a mechanistic link between 
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these findings and the etiology of PAH, future therapies to manipulate the 
control of NO homeostasis by the HIFα pathway should certainly be explored.  
 
Pulmonary hypertension due to chronic hypoxia is a progressive disease, that 
leads eventually to right heart failure and death.  The pathogenesis of this 
condition involves proliferation of endothelial and smooth muscle cells, 
resulting in vascular remodeling of the pulmonary arterioles. Here we identify 
an essential role for pulmonary endothelial HIF2α expression, and its 
regulation of arginase, in both the physiological response to acute hypoxia, 
and the vascular remodelling processes that characterise chronic hypoxic 
exposure. 
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Methods 
Animals.  All animals were housed in an Association and Accreditation of 
Laboratory Animal Care International-approved facility.  All protocols and 
surgical procedures were approved by the local and national animal care 
committees. 
Targeted deletion of HIF-1α, HIF-2α and arginase-1 in pulmonary endothelial 
cells was created by crossing (C57Bl6/j) homozygous for the floxed allele in 
HIF-1α, HIF-2α or arginase-1 into a background of Cre recombinase 
expression drive by the L1 (alk-1) promoter kindly donate by Dr Paul Oh, 
Florida University.(29)   Mice characterized as wild type (WT) were in all 
cases littermates of respective mutant mice, homozygous for conditional 
alleles but without the cre recombinase transgene. 
 
Measurement of Right Ventricular Systolic Pressure (RVSP).  For 
induction of PAH due to chronic hypoxia, groups of male mice (8-12 weeks) 
were maintained in a normobaric hypoxic chamber (FiO2 10%) for up to 21 
days. Mice were weighed then anesthetised (isoflurane) and right-sided heart 
catheterisation through the right jugular using a pressure-volume loop 
catheter (Millar).(51-53)  Bloods were taken for haemodynamic assessment. 
 
Right Ventricular Hypertrophy.  To measure the extent of right ventricular 
hypertrophy (RVH), the heart was removed and the right ventricule (RV) free 
wall was dissected from the left ventricle plus septum (LV+S), and weighed 
separately.(54)  The degree of RVH was determined from the ratio RV/LV+S. 
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Tissue Preparation.  In all animals the left lung was fixed in situ in the 
distended state by the infusion of 0.8% agarose into the trachea, and then 
placed in 10% paraformaldehyde before paraffin embedding.  The right lung 
was frozen in liquid nitrogen for mRNA extraction. 
 
Pulmonary Vascular Morphometry.  Lung tissues were stained with 
hematoxylin and eosin, sirius red or elastic van Gieson (EVG) stain to assess 
morphology (all Merck/BDH, Lutterworth UK).  To determine the degree of 
muscularization of small pulmonary arteries, serial lung tissue sections were 
stained with anti-smooth muscle α-actin (α-SMactin; DakoCytomation Ely UK) 
and von Willebrand factor (DakoCytomation).  Antibody staining was 
visualised using 3-3’ diaminobenzidine hydrochloride substrate 
(DakoCytomation) and counterstained with Carrazzi hematoxylin (Bios 
Shelmersdale UK).  Vessel medial thickness was measured using Image J 
software (MediaCybernetics, Bethesda MD) 
 
Haematological Analysis. Anti-coagulated blood was analysed using Vet 
abc haematology analyser (Horiba) according to the manufacturers 
instructions. 
 
Nitrite/Nitrate Analysis.  Blood samples were centrifuged to separate plasma 
and were passed through a column with a 10-kDa cut-off filter.  All samples 
were analysed for total NO(X) content using a NOA 280i (Siever, GE 
Healthcare) according to the manufacturers instructions. 
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RNA Analysis. Total RNA and DNA was isolated from the lung using TRI-
reagent (Sigma) followed by RNA clean-up and DNase digest using RNeasy 
column kits (Qiagen).  First-strand synthesis was performed with 1µg of total 
RNA using a high-capacity cDNA kit (Applied Biosystems) according to the 
manufacturers instructions.  Relative gene expression was determined by 
quantitative PCR (qPCR) (One-Step Plus Real-Time PCR System; Life 
Technologies) and was amplified in SYBR-Green master mix (Roche) and 
relevant primers from Qiagen.  Relative gene-expression levels were related 
to β-actin and B2M using the 2ΔΔCT method. 
 
Statistical Analysis. All data represents the mean (±SEM) of n separate 
experiments unless otherwise stated.  Difference between groups were 
assessed using t test unless otherwise stated.  A p value of <0.05 was 
considered significant. 
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Figure Legends 
Figure 1. Pulmonary endothelial HIF-2α modulates chronic hypoxic 
pulmonary hypertension. (A) Scatter plot (mean ± SEM) shows the effect of 
pulmonary endothelial HIFα on right ventricular systolic pressure (RVSP).  
Wild-type (WT) and L1cre-HIFα mice were housed in normoxia (N) or chronic 
hypoxia (H) (WT (N) n=9 (H) n=12; L1cre-HIF-1α (N) n= 6 (H) n=7; L1cre-HIF-
2α (N) n=11 (H) n=7). (B) Effect of pulmonary endothelial HIFα on right 
ventricular hypertrophy.  Scatter plot (mean ± SEM) show RV/LV+S weight 
ratio in mice exposed to normoxia (N) or chronic hypoxia (H) (WT (N) n=9 (H) 
n=12; L1cre-HIF-1α (N) n= 6 (H) n=7; L1cre-HIF-2α (N) n=11 (H) n=7). 
*P<0.05, **P<0.001, ***P<0.0001 
 
Figure 2. Pulmonary endothelial HIF-2α is essential for airway remodelling in 
chronic hypoxic pulmonary hypertension.  (A and B) Airway remodelling was 
determined in wild-type (WT) (n=15), L1cre-HIF-1α (n=7) and L1cre-HIF-2α 
(n=7) post chronic hypoxic challenge. (A) Histological sections of lung were 
immunostained with α−smooth-muscle actin(α-SMA), von Willebrand 
factor(vWF), and Elastic van Gieson (EVG).  Representative 
photomicrographs demonstrate the remarkable lack of remodelling in L1cre-
HIF-2α pulmonary arteries associated with terminal bronchi when compared 
to WT or L1cre-HIF-1α mice. (B) Scatter plot (mean ± SEM) shows the effect 
of pulmonary endothelial HIFα on vessel medial thickness.  Quantification of 
the intimal medial thickness achieved by staining lung sections with EVG.  
Measurement of vessel thickness as a percentage of total vessel area by 
image J software. ***P<0.0001. 
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Figure 3.  Loss of HIF-2α in pulmonary endothelial cells reduces the degree 
of muscularization of peripheral arteries.  Stacked bar chart showing the 
degree of muscularization of peripheral pulmonary arteries in lung sections 
from wild-type (WT) (n=15), L1cre-HIF-1α (n=9) and L1cre-HIF-2α (n=7) mice.  
Representative photomicrographs immunostained for α-smooth muscle actin 
showing near and complete ring formation in peripheral vessel of WT and 
L1cre-HIF-1α mice when compared to L1cre-HIF-2α mice (arrows point to 
distal vessels). 
 
Figure 4.  Endothelial deletion of HIF-2α maintains higher plasma nitrate 
levels potentially through lower arginase expression in pulmonary 
endothelium.  (A) qPCR analysis of arginase-I/-II, NOS2, and VEGF mRNA 
from whole lung samples of wild-type (WT) (open bar, n=7), L1cre-HIF-1α 
(dark grey bar, n=7) and L1cre-HIF-2α (closed bar, n=6). (B) Total nitric oxide 
was determined in the plasma by the conversion of NOx to NO using a nitric 
oxide analyser (Siever).  Data shown as scatter plot with mean ± SEM from 
WT (n=7), L1cre-HIF-1α (n=7) and L1cre-HIF-2α (n=6) post chronic hypoxia 
challenge. *P<0.05. 
 
Figure 5.  Pulmonary endothelial deletion of Arg-1 attenuates hypoxic 
pulmonary hypertensive phenotype.   A) Scatter plot (mean ± SEM) shows the 
effect of pulmonary endothelial Arg-1 on right ventricular systolic pressure 
(RVSP).  Wild-type (WT) and L1cre-Arg1 mice were housed in normoxia (N) 
or chronic hypoxia (H) (WT (N) n=5 (H) n=7; L1cre-Arg1 (N) n= 6 (H) n=7. (B) 
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Effect of pulmonary endothelial Arg-1 on right ventricular hypertrophy.  Scatter 
plot (mean ± SEM) show RV/LV+S weight ratio in mice exposed to normoxia 
(N) or chronic hypoxia (H) (WT (N) n=6 (H) n=6; L1cre-Arg1 (N) n= 7 (H) n=9. 
(C) Airway remodelling was determined in wild-type (WT) (n=8), L1cre-Arg1 
(n=10).  Quantification of the intimal medial thickness achieved by staining 
lung sections with EVG.  Measurement of vessel thickness as a percentage of 
total vessel area by image J software. (D) Stacked bar chart showing the 
degree of muscularization of peripheral pulmonary arteries in lung sections 
from wild-type (WT) (n=5), L1cre-Arg1 (n=6) mice.  Representative 
photomicrographs immunostained for α-smooth muscle actin showing near 
and complete ring formation in peripheral vessel of WT mice when compared 
to L1cre-Arg1 mice. (E) Total nitric oxide was determined in the plasma by the 
conversion of NOx to NO using a nitric oxide analyser (Siever).  Data shown 
as scatter plot with mean ± SEM from WT (n=6), L1cre-Arg1 (n=8) post 
chronic hypoxia challenge; *P<0.05, **P<0.001, ***P<0.0001. 
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Supplemental Figures: 
 
Supplemental Figure 1. L1cre specificity for pulmonary endothelial cells.  
Representative photomicrographs from 3 independent mice (A) show bright-field 
structure of frozen lung sections, strong positive fluorescent endothelial cells and 
combined overlay.  (B) Frozen tissue sections taken from representative organs 
in the same L1cre mouse.  Little to no positive fluorescent cells were seen in 
other tissues. (C) L1cre deletion efficiency of HIF-2α in isolated pulmonary 
endothelial cells and other selected organs. Isolated endothelial data shown as 
single experiment from six pooled animals.   
 
Supplemental Figure 2.  Haematological and body weight response to chronic 
hypoxia.  (A and B)  Red blood cell counts (RBC), haemoglobin (HGB) scores 
and white cell counts (WBC) did not deviate between the groups (A) Data shown 
as scatter graph as mean ± SEM of RBC and HGB from normoxic (N) and 
chronic hypoxic (H) housed wild-type (WT) (n=9 and n=15) L1cre-HIF-1α (n=9 
and n=8) and L1cre-HIF-2α (n=7 and n=8).  (C) Bar graph of mean ± SEM body 
weight, normoxic (N) and after chronic hypoxia (H) from WT (n=8), L1cre-HIF-1α 
(n=7) and L1cre-HIF-2α (n=8). 
 
Supplemental Figure 3.  Histological sections from paraffin wax embedded 
lungs were immunostained for αSmooth-Muscle actin, von Willebrand factor, and 
stained for hematoxylin & eosin and Elastic van Gieson (EVG).  Representative 
photomicrographs show no remodelling in normoxic housed L1cre-HIF-1α or 
L1cre-HIF-2α mice when compared to wild-type control. 
 
Supplemental Figure 4. Deletion of pulmonary endothelial HIF-2α decreases 
collagen deposition around arteries associated with terminal bronchus.  
Histological lung sections were stained using Sirius red and then analysed by 
image J software.  Data shown as bar graph for wild-type (WT) (open bar, n=7), 
L1cre-HIF-1α (grey bar, n=6) and L1cre-HIF-2α (closed bar, n=7).  
Representative photomicrographs show the degree of collagen deposition 
following chronic hypoxic challenge. **P<0.001 
 
 
Supplemental Figure 5.  Arginase and Endothelin-1 expression in isolated 
pulmonary endothelial cells and whole lung.  (A and B) QPCR data from a single 
experiment of six pool animals, pulmonary endothelial cells isolated from wild-
type or L1cre-HIF-2α mice culture in normoxia or hypoxia for 24hrs. (C) QPCR 
analysis of ET-1 expression in whole lung tissue from wild-type (n=15), L1cre-
HIF-1α (n=7) and L1cre-HIF-2α (n=6) mice following chronic hypoxic challenge.  
(C) Acute hypoxic increase in plasma endothelin-1 was inhibited in the L1cre-
HIF1a (n=4) and L1cre-HIF2a (n=4) mice when compared to wild-type (n=6). 
Data bar shown as mean ± SEM 
 
Supplemental Figure 6. Red blood cell counts (RBC), haemoglobin (HGB) did 
not deviate between the groups (A) Data shown as scatter graph as mean ± SEM 
of RBC and HGB from normoxic (N) and chronic hypoxic (H) housed wild-type 
(WT) (n=6(N) and 4(H)) L1cre-Arg1 (n=6 (N) and n=9(H)) (B) Histological 
sections of lung were immunostained with α−smooth-muscle actin(α-SMA), von 
Willebrand factor(vWF), and Elastic van Gieson (EVG).  Representative 
photomicrographs demonstrate the attenuation of remodelling in L1cre-Arg1 
pulmonary arteries associated with terminal bronchi when compared to WT 
controls. 
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